Clinical trials: AMI Patients
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Romania Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01593059
- Where
- 4 sites in Romania
- Volunteers
- 13 people
- Sponsor
- Biotronik Vertriebs-GmbH
Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
The goal of this phase IIc clinical trial is to learn if recombinant human thymosin beta 4 injection (NL005) works to treat heart damage in people who have had a serious type of heart attack called ST-segment elevation myocardial…
- Conditions
- Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall, Acute Myocardial Infarction With ST Elevation, Acute Myocardial Infarction of Left Ventricle
- Trial name
- NCT07586865
- Testing
- Recombinant Human Thymosin Beta 4 Injection (NL005)
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
Acute Myocardial Infarction
CARISMA : Cardiac Arrhythmias and Risk Stratification After MyoCardial Infarction
The purpose of this study is to assess the incidence of tachy- and bradyarrhythmic episodes in patients with acute myocardial infarction with depressed ventricular function and to determine the predictive value of several…
- Trial name
- NCT00145119
- Where
- Netherlands
- Volunteers
- 312 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Nonfatal Myocardial Infarction, Coronary Death
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and…
- Trial name
- NCT01360073
- Where
- 2 sites in Spain, Sweden
- Volunteers
- 42,542 people
- Sponsor
- AstraZeneca
Coronary Artery Diseases
BIOTRONIK - BIOFLOW-III Registry French Satellite
For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success.
- Trial name
- NCT02273648
- Testing
- Drug Eluting Stent (DES)
- Where
- 50 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Biotronik France
Post Acute Coronary Syndrome, Myocardial Ischemia
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular…
- Trial name
- NCT00409578
- Testing
- Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 1,101 people
- Sponsor
- Novartis
Stroke, Stroke, Ischemic
MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits
This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501…
- Conditions
- Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae
- Trial name
- MAESTOSO (NCT05289947)
- Testing
- MLC1501
- Where
- 11 sites in Philippines, Singapore
- Volunteers
- 303 people
- Sponsor
- Moleac Pte Ltd.
Acute Myocardial Infarction
Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration
This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.
- Trial name
- NCT07400458
- Testing
- Hearticellgram-AMI
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Pharmicell Co., Ltd.
Myocardial Infarction
Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction
To monitor the safety of Metalyse® in clinical practice in patients with acute myocardial infarction over a period of 6 years as required by Korean authorities, with the following observations: 1.
- Trial name
- NCT02206646
- Testing
- Metalyse
- Volunteers
- 987 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
First-in-Human Study Using the SiroMax™ Sirolimus-Coated Balloon Catheter as a Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter to Treat Subjects Who Have Coronary Artery Disease (CAD) Involving In-Stent Restenosis (ISR) or an Unstented Lesion in a Small Coronary Vessel (DNSV).
The goal of this clinical trial is to learn if the SiroMax™ drug-coated balloon catheter is safe and works to treat stenotic coronary lesions in adults.
- Conditions
- Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), In-Stent Restenosis or De Novo Coronary Artery Lesions, In-Stent Stenosis (Restenosis) of Coronary Artery Stent
- Trial name
- SMART-I (NCT07811024)
- Testing
- Sirolimus-coated balloon catheter
- Where
- 2 sites in Uzbekistan
- Volunteers
- 60 people
- Sponsor
- Tonic Medical, Inc.
Cardiogenic Shock, Heart Failure
Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock
The Elevate™ CS Clinical Feasibility Study is designed to evaluate the initial safety, effectiveness, and device performance of the Magenta Elevate™ System in patients with cardiogenic shock due to isolated or predominant left…
- Conditions
- Cardiogenic Shock, Heart Failure, Acute Myocardial Infarction (AMI)
- Trial name
- NCT07293923
- Testing
- Elevate™ System
- Where
- 8 sites in Georgia, Israel
- Volunteers
- 10 people
- Sponsor
- Magenta Medical Ltd.
ST Elevation Myocardial Infarction
Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction
Patients with ST-segment elevation myocardial infarction (STEMI) that have suffered a major anterior wall infarction or where coronary blood flow is less than normal in spite of successful percutaneous coronary intervention (PCI)…
- Trial name
- NCT03991143
- Testing
- ATH3G10
- Where
- Sweden
- Volunteers
- 82 people
- Sponsor
- Athera Biotechnologies AB
Unstable Angina, Myocardial Infarction
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention [PCI]…
- Conditions
- Unstable Angina, Myocardial Infarction, Acute Disease
- Trial name
- NCT00093158
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 13,800 people
- Sponsor
- The Medicines Company
Acute Myocardial Infarction
COOL-AMI EU Case Series Clinical Study
A single-center, prospective case series clinical study consecutively enrolling up to 10 patients with expected duration of 12 months or less.
- Trial name
- NCT02070913
- Where
- 23 sites in Czechia, Estonia and 6 more
- Volunteers
- 352 people
- Sponsor
- ZOLL Circulation, Inc., USA
Acute Coronary Syndromes
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary…
- Trial name
- ACCOAST (NCT01015287)
- Testing
- Prasugrel
- Where
- 153 sites in Austria, Belgium and 17 more
- Volunteers
- 4,033 people
- Sponsor
- Eli Lilly and Company
STEMI
The Coronary Sinus Balloon Pump in STEMI
This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of the coronary sinus balloon pump (manufactured by Shanghai MicroPort Rotapace Medical Technology Co.…
- Trial name
- REVIVE-RCT (NCT07354035)
- Testing
- The coronary sinus balloon pump, Percutaneous Coronary Intervention (PCI)
- Volunteers
- 177 people
- Sponsor
- Shanghai MicroPort Rhythm MedTech Co., Ltd.
Acute Myocardial Infarction
A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
The primary purpose of this study is to assess the safety of INO-1001 in subjects who have experienced a heart attack and are to be treated with coronary angioplasty.
- Trial name
- NCT00271765
- Testing
- INO-1001
- Where
- 16 sites in United States, Israel
- Volunteers
- 40 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Thromboembolism
OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction
This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of…
- Trial name
- NCT00064428
- Testing
- fondaparinux - UFH not indicated, Control - UFH not indicated, Fondaparinux - UFH indicated
- Volunteers
- 12,092 people
- Sponsor
- GlaxoSmithKline
Heart Failure, Acute Myocardial Infarction
Carvedilol Vascular Efficacy Trial
Beta-blockers should be administered to all patients with heart failure stages II to IV NYHA. It should also be administered to patients with stage I after myocardial infarction.
- Trial name
- CARVEDIA (NCT01484327)
- Testing
- Carvedilol
- Where
- Greece
- Volunteers
- 415 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Shock, Cardiogenic
A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.
The objective of this Phase 1b/2a trial is to evaluate the safety, tolerability, and exploratory efficacy of invobenitug (also known as procizumab), a monoclonal antibody under development for the treatment of cardiogenic shock…
- Trial name
- PROCARD 2a (NCT06832722)
- Testing
- AK1967 (Invobenitug also known as Procizumab)
- Where
- 37 sites in Armenia, Belgium and 7 more
- Volunteers
- 90 people
- Sponsor
- 4TEEN4 Pharmaceuticals GmbH